Latest news

• Sanofi warns of difficult few months as diabetes sales slump

  vaccine Dengvaxia and supply issues for paediatric vaccines in China.

• Sanofi sells European generics to Advent for $2.4bn

  such as dengue fever vaccine Dengvaxia to deliver revenues as expected.

• Sanofi backs vaccines unit with €350m Canadian facility

  vaccine Dengvaxia last year, as well as lumpy orders for its meningitis vaccine Menactra and overall static sales of paediatric combination shots. ... Sanofi’s vaccines sales grew 8.3% overall last year, but growth shrank to 1.2% in the fourth-quarter,

• Sanofi taps Evotec for new anti-infectives drive

  stage pipeline setbacks, including big problems for new dengue fever vaccine Dengvaxia.

• Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

  It’s also suffered a couple of major setbacks in its pipeline, including the failure of its dengue vaccine Dengvaxia which had been tipped as a blockbuster but is now looking ... In the Philippines - one of the only countries to use the vaccine